
Synthesis and Properties of π -Complexes of Morphine Alkaloids with Palladium

Valery N. Kalinin,^{*a} Irina L. Belyakova,^a Vladimir V. Derunov,^a Jin K. Park^b and
Helmut Schmidhammer^c

^a A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 117813 Moscow,
Russian Federation. Fax: +7 095 135 5085

^b Dong Kook Pharmaceutical Co., Ltd., Dae Chi-3 Dong, Kang Nam-Ku, 997-8 Seoul, Korea. Fax: +02 566 8542

^c Institute of Pharmaceutical Chemistry, University of Innsbruck, Inrain 52a, A-6020 Innsbruck, Austria.
Fax: +43 512 507 3313

Treatment of 6 β -chloro-6-deoxycodine **1** with Pd(PPh₃)₄ yields 6-demethoxythebaine **2** and the π -allylic palladium complex **3**, which further reacts with RZnX to give the cross-coupling product of the allylic ligand and R (compounds **5** and **6**, respectively). The same products are formed upon reaction of 6 β -chloro-6-deoxycodine **1** with RZnX in the presence of catalytic amounts of Pd(PPh₃)₄.


Reactions of transition metal complexes with morphine alkaloids are useful for the stereocontrolled introduction of substituents into the morphinan skeleton and for protection of ring C against further modification of the morphine alkaloids.^{1–4}

It has been found previously that codeine and morphine react with aryl iodides in the presence of catalytic amounts of

palladium(II) salts to give 8 β -aryldihydrocodeinones and -morphinones.^{5,6} Reactions of 6 α -xanthate-6-deoxycodine and 8 α -dithiocarbonate-8-deoxypseudocodeine with Pd(PPh₃)₄ leads to elimination of the corresponding thioacids to give 6-demethoxythebaine.⁷ It is known that heating of 3-acetoxy-cyclohex-1-ene in the presence of a palladium catalyst results in elimination of acetic acid and formation of cyclohexadiene.


For example, treatment of 3-acetoxo-5-carbomethoxycyclohex-1-ene with 5% $\text{Pd}(\text{PPh}_3)_4$ afforded 5-carbomethoxycyclohexa-1,3-diene.⁸

We have found that 6 β -chloro-6-deoxycodeine **1** reacts with $\text{Pd}(\text{PPh}_3)_4$ to give two products: 6-demethoxythebaine **2**⁹ and the π -allylic palladium complex **3** (Scheme 1).




Scheme 1 Reagents and conditions: i, THF, 0°C , 4 h.

One may suggest that oxidative addition of $\text{Pd}(\text{PPh}_3)_4$ occurs during this reaction and that π -allylic intermediate **A** is formed followed by its reductive elimination to give **2** and **3** (Scheme 2).



Scheme 2

We have found that reaction of **3** with NaI results only in the exchange of the halogen atom to give complex **4** (Scheme 3).




Scheme 3 Reagents and conditions: i, THF, 0°C , 0.5 h.

Reaction of **3** with RZnCl leads to 6 β -substituted derivatives of 6-deoxycodeine (compounds **5** and **6**, respectively), which were identical with authentic samples.^{10,11} The same products (**5** and **6**) were obtained by reaction of **1** with RZnCl in the presence of catalytic amounts of $\text{Pd}(\text{PPh}_3)_4$ (Scheme 4).

Since compound **1** does not react with RZnCl alone, one may assume that the reaction proceeds *via* complex **3**.

These are the first examples of π -complexes of morphine alkaloids with palladium. The proposed reaction presents



Scheme 4 Reagents and conditions: i, THF, -20°C , 10% $\text{Pd}(\text{PPh}_3)_4$, 1 h; **5**: yield 28%; **6**: yield 40%; ii, THF, -20°C , 1 h; **5**: yield 33%; **6**: yield 42%.

significant potential for the introduction of different substituents into ring C of morphine alkaloids *via* palladium-catalysed cross-coupling reactions.

All new complexes gave satisfactory analytical and spectroscopic data.[†]

This work was supported by grants from INTAS (93-1588), the International Research Foundation (MAB000) and the Russian Foundation for Fundamental Research (93-03-4403).

References

- 1 V. N. Kalinin and N. I. Kobel'kova, *Zh. Vses. Khim. O-va im. D.I.Mendeleeva*, 1991, **26**, 443 (in Russian).
- 2 A. J. Birch, *Aust. J. Chem.*, 1969, **22**, 971.
- 3 K. W. Bentley, *Chemistry of Alkaloids*, Van Nostrand Rheinhold Co., New York, 1970, 117.
- 4 A. J. Birch, L. F. Kelly and A. J. Liepa, *Tetrahedron Lett.*, 1985, **26**, 501.
- 5 V. N. Kalinin, S. A. Kazantseva, P. V. Petrovskii, N. I. Kobel'kova, A. V. Polyakov, A. I. Yanovsky and Yu. T. Struchkov, *Dokl. Akad. Nauk SSSR*, 1988, **298**, 119 [*Dokl. Chem. (Engl. Transl.)*, 1988, **298**, 11].
- 6 V. N. Kalinin, S. A. Kazantseva, P. V. Petrovskii, N. I. Kobel'kova, Yu. D. Ignatov, E. E. Zvartau and M. I. Dorokhova, *Khim. Farm. Zh.*, 1989, 48 (in Russian).
- 7 I. Fujii, M. Koreyuki and K. Kanematsu, *Chem. Pharm. Bull.*, 1988, **36**, 1750.
- 8 B. M. Trost, T. R. Verhoeven and J. M. Fortunak, *Tetrahedron Lett.*, 1979, **25**, 2301.
- 9 C. W. Hutchins, G. K. Cooper, S. Pürro and H. Rapoport, *J. Med. Chem.*, 1981, **24**, 773.
- 10 V. N. Kalinin, I. L. Belyakova, V. V. Kobak, P. V. Petrovskii, A. I. Yanovsky and Yu. T. Struchkov, *Mendeleev Commun.*, 1993, 12.
- 11 V. N. Kalinin, I. L. Belyakova, V. V. Derunov, P. V. Petrovskii, A. I. Yanovsky, Yu. T. Struchkov, H. Schmidhammer and J. K. Park, *Helv. Chim. Acta*, 1994, **77**, 164.

Received: Moscow, 22nd September 1994
Cambridge, 17th October 1994; Com. 4/058871

[†] **3**: yield 31%, m.p. 119–120°C (decomp.); ¹H NMR (200 MHz, CDCl_3): δ 2.38 (s, 3H, MeN), 3.77 (s, 3H, MeO), 3.85 (m, 1H, H-6), 3.90 (d, 1H, J 2.6 Hz, H-5), 5.14–5.90 (m, 2H, H-7, H-8), 6.55 and 6.65 (2d, J 8.2, 8.2 Hz, H-1, H-2), 7.19–7.82 (m, 15 arom. H).

4: yield 68%; m.p. 125–126°C (decomp.); ¹H NMR (200 MHz, CDCl_3): δ 2.35 (s, 3H, MeN), 3.72 (s, 3H, MeO), 3.79 (m, 1H, H-6), 4.25 (d, 1H, J 2.7 Hz, H-5), 5.10–5.76 (m, 2H, H-7, H-8), 6.50 and 6.60 (2d, J 8.2, 8.2 Hz, H-1, H-2), 7.36–7.65 (m, 15 arom. H).